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Cardiovascular determinants of life span
Abstract
The prevalence of cardiovascular diseases rises with aging and is one of the main causes of mortality in
western countries. In view of the progressively aging population, there is an urge for a better
understanding of age-associated cardiovascular diseases and its underlying molecular mechanisms. The
risk factors for cardiovascular diseases include unhealthy diet, diabetes, obesity, smoking, alcohol
consumption, physical inactivity, and aging. Increased production of oxygen-derived free radicals plays
an important role in mediating cardiovascular diseases. Oxidative stress affects the availability and/or
balance of key-regulators of vascular homeostasis and favors the development of cardiovascular
diseases. Reactive oxygen species are generated by different intracellular molecular pathways
principally located in the cytoplasm and in the mitochondria. The mitochondrial protein p66Shc and the
deacetylase enzyme SIRT1 were shown to be involved in different aspects of cardiovascular diseases.
This review focuses on the latest scientific advances in understanding cardiovascular diseases associated
to aging, as well as delineating the possible therapeutic implications of p66Shc and SIRT 1 in this
process.
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Abstract 
The prevalence of cardiovascular diseases rises with aging and it is one of the main causes of 
mortality in western countries. Thus there is an urge for a better understanding of 
cardiovascular diseases and underlying molecular mechanisms. The risk factors for 
cardiovascular diseases include unhealthy diet, diabetes, obesity, smoking, alcohol 
consumption, physical inactivity and aging. Increased production of oxygen-derived free 
radicals plays an important role in mediating cardiovascular diseases. Oxidative stress affects 
the availability and/or balance of key-regulators of vascular homeostasis and favours the 
development of cardiovascular diseases. Reactive oxygen species are generated by different 
intracellular molecular pathways principally located in the cytoplasm and in the mitochondria. 
The mitochondrial protein p66Shc and the deacetylase enzyme SIRT1 were shown to be 
involved in different aspects of cardiovascular diseases. This review focuses on the latest 
scientific advances in understanding cardiovascular diseases as well as delineating the 
possible therapeutic implications of p66Shc and SIRT 1 in this process. 
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Introduction  
To date, cardiovascular disease is the leading cause of death in western countries. Although 
the absolute incidence and mortality of cardiovascular disease are falling, there are still a 
certain amount of deaths before average of life expectancy elapses. Thus, there is an urge for 
more efforts by the scientific community to identify new mediators and/or novel therapeutic 
targets for cardiovascular disease.  
Cardiovascular disorder are a heterogeneous entity encompassing risk factor such as 
hypertension, diabetes, smoking, obesity, and aging as well as true cardiac conditions such as 
coronary artery disease, infarction, and heart failure. However they do share abnormalities in 
arterial wall. Usually endothelial dysfunction is the earliest disturbance, but rather difficult to 
be diagnosed before symptoms. The present non-exhaustive review discussed several latest 
scientific advances in molecular levels. 
Elevated oxidative stress and vascular dysfunction 
Endothelium, the inner-most layer of the vascular wall, offers a primary protection against 
vascular dysfunction, occurrence of atherosclerosis and thrombogensis. Under physiological 
conditions, a balance between reactive oxygen species (ROS) damage and endothelial 
progenitor cell-mediated repair keeps the integrity of endothelium and maintains endothelial 
functions [1]. However under pathophysiological conditions, this balance shifts towards ROS-
induced damage which is due to additional cellular damage by protein oxidation and/or 
decreased endothelial progenitor cells’ function [2, 3] (Figure 1).  
Nitric oxide (NO), the principle endothelial derived relaxing factor [4, 5], has inhibitory 
effects on endothelium-derived contracting factors [4, 5]. When the release of NO is reduced 
and the production of endothelium-derived contracting factors is enhanced, endothelial 
dysfunction ensues [4]. In addition, nitric oxide plays a key role in preventing atherosclerosis 
by reducing the adhesion of platelets and leukocytes [6, 7] and by inhibiting the migration and 
proliferation of smooth muscle cells [8].  
A large body of evidences reports a reduced blood flow in aged people or patients with 
hypertension, hypercholesterolemia, atherosclerosis, heart failure or diabetes [9-11]. The 
phenomenon is replicated in pertinent animal models and is shown to have a reduced NO 
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bioavailability and/or an enhanced endothelium-dependent vasoconstriction [12-15]. These 
studies confirm endothelial dysfunction in cardiovascular disorders in human. 
The elevated levels of superoxide anion (O2-) observed under disease conditions are a crucial 
factor for the loss of NO availability in endothelial cells, since the expression of endothelial 
nitric oxide synthase (eNOS) in diseases is either declined [16] or preserved [17]. Superoxide 
anion (O2-) inactivates NO in few seconds and further generates another highly reactive 
species, peroxynitrite (ONOO-). Peroxynitrite penetrates across the phospholipid membrane 
and produces substrate nitration, thereby damaging DNA [18], inducing oxidation 
modification of lipoprotein[19], disrupting mitochondrial function [20-22], and depleting 
plasma antioxidants [23].  
The increased production of ROS under disease conditions is also implicated in 
proinflammatory processes by directly acting as second messengers. For instance, ROS 
activate NF-κB, a key transcription factor [24]. Activation of NF-κB in turn promotes the 
transcription of several critical genes in atherogenesis, including cytokines such as tumor 
necrosis factor-α (TNF-α) and interleukin 6 (IL-6), monocyte chemoattractant protein-1 
(MCP-1) and adhesion molecules (VCAM-1) [25-31]. Thus, oxidative stress is regarded as a 
key factor contributing to chronic inflammation [24]. 
Oxidative stress in cardiovascular disease 
A large body of evidences underscores a critical role for oxygen free radicals in endothelial 
injury, aging and cardiovascular diseases [4, 32-35]. 
Aging shares several pathophysiological features with cardiovascular diseases [36, 37]. The 
free radical theory of aging is currently accepted as the reference concept describing the 
mechanism underlying aging and aging-related diseases [16, 38-43]. The increased production 
of ROS in aging is associated with enhanced peroxynitrite formation [43], upregulated 
expression of inducible nitric oxide synthase (iNOS) [16], NAD(P)H oxidase [44], and/or a 
parallel downregulation of antioxidants, such as extra cellular SOD (ecSOD) [45] and 
decreased catalase activity [17].  
The development of atherosclerosis is considered to be increased levels of oxidative stress 
and oxidative stress induced chronic inflammation. The source of free radical species in 
atherosclerosis can be iNOS [46, 47], NAD(P)H oxidase [48], and/or cyclooxygenase-2 [49]. 
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Importantly reactive oxygen species modify the low-density lipoprotein to oxidized low 
density protein which as profound biological effects via LOX-1 receptor in endothelial cells 
and scavenger receptor-A (SR-A) in macrophages [50-53]. In addition to the decrease of 
eNOS activity [54-56], oxLDL increases the expression of VCAM-1 and MCP-1 protein 
through NF-κB-mediated gene transcription [53, 57]. Thus, this implies a complicated ROS-
mediated inflammation in the occurrence of atherosclerosis. 
Diabetes is an important risk factor for cardiovascular diseases [35]. The increased production 
of free radicals results from a reduced activity of superoxide dismutase [55-59], reduced 
expression of heme oxygenase [58],  as well as from enhanced expression of NAD(P)H 
oxidase [59-61] and cyclooxygenase [14, 62, 63]. In addition, the unique glycation reaction in 
diabetes produces more pronounced oxidative free radicals through intermediate compounds 
that in turn increase the levels of reactive oxygen species [35, 64-71]. Dicarbonyl compounds 
such as methyglyoxal and 3-deoxyglucosone, intermediate products of glycation, are typical 
examples. The serum concentrations of both methyglyoxal and 3-deoxyglucosone are 
increased in patients with diabetes mellitus [72], indicating that free radicals play a crucial 
role in the pathogenesis of diabetes-associated complications [64, 73].  
 
The ROS sensitive protein p66Shc  
The mitochondrial adaptor protein p66Shc is regarded as an important mediator of aging since 
genetic deletion of p66Shc protein in the mouse causes lower levels of ROS and prolongs 
lifespan by 30% [74]. The mammalian Shc locus encodes for three different adaptor proteins 
with respective molecular masses of 46, 52 and 66 kDa. The splice variant p66Shc is the only 
isoform to participate in mitochondrial ROS generation and thus to translate oxidative signals 
into apoptosis [74-77]. In fact, in the absence of p66Shc mitochondrial oxidative 
phosphorylation is reduced in favor of glycolysis. In light of its pivotal role in ROS 
generation, many efforts have been made to investigate the pathophysiological role of p66Shc 
in ROS-mediated diseases [78, 79].  
The expression pattern of p66Shc protein in humans was studied in young people, elderly and 
centenarians. The expression of p66Shc in fibroblasts was shown to increase with age [80], 
suggesting that the expression of p66Shc protein concurs with the process of aging. In human 
peripheral blood monocytes, p66Shc mRNA expression is enhanced in diabetic patients 
compared to healthy subjects [81]. Given the upregulated expression of p66Shc in aged 
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people and diabetic patients, the hypothesis that this mitochondrial adaptor protein p66Shc is 
linked to aging and/or ROS related diseases has been widely accepted. Genetic knockout mice 
is a useful tool to study the role of  p66Shc protein under pathophysiological conditions since 
identical Shc genomic organization, transcript assembly as well as a high degree of amino 
acid identity have been reported in mice and in humans [82].  
In adipose cell culture experiments, insulin treatment increased the production of ROS in 
brown pre-adipocytes of wild type mice, but not in those from p66Shc knockout mice. 
Reintroduction of p66Shc ex vivo restored the insulin-stimulated ROS production in pre-
adipocytes of p66Shc knockout mice, confirming that p66Shc plays a crucial role in ROS 
production [83]. Further p66Shc knockout mice are resistant to high fat diet induced obesity, 
shown as increased basal metabolism, reduced fat development, and increased insulin 
sensitivity of peripheral tissues [83]. This result implies that p66Shc is an important mediator 
in insulin-signaling pathway and in energetic metabolism.  
In line with the above, a blunted age-dependent and NO-mediated vasodilatation was 
maintained in the aorta of age-matched p66Shc knockout mice (Figure 2), demonstrating that 
a preserved NO bioavailability in aged p66Shc knockout mice is due to lower aortic O2- levels 
and reduced aortic 3-nitrotyrosine content [84]. Thus this suggests a potentiating mechanism 
of preserved NO availability in p66Shc knockout mice. Therefore, p66Shc adaptor protein has 
been regarded as a key player in age-dependent loss of endothelial integrity. 
The beneficial effects of the deletion of p66Shc protein are also observed in apoE knockout 
mice [79, 85].  High fat diet induces comparably high levels of serum lipid in both control and 
p66Shc knockout mice. However p66Shc knockout mice have a lower level of lipid 
peroxidation than control mice. This suggests a putative role of p66Shc in the oxidation 
modification of lipoprotein. Thus, p66Shc knockout mice are protected from high fat diet 
induced aortic lesion due to a decreased oxidative stress and a decreased formation of foam 
cells [85]. This underscores that p66Shc takes part in the development of ROS-mediated 
atherosclerotic lesion. 
In line with the observation that p66Shc expression was increased in diabetic patients [81], 
the expressions of p66Shc protein are enhanced in aorta and renal cortex of streptozotocin-
induced type I diabetic mice [58, 86]. Higher glucose levels in serum were comparable in 
p66Shc knockout and wild type mice [58, 86, 87], indicating that the deletion of p66Shc 
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protein does not affect the diabetic condition as well as hyperglycemia. Nevertheless p66Shc 
knockout mice are protected from diabetes-induced endothelial dysfunction [58] and diabetic 
glomerulopathy [87], which is due to reduced productions of ROS and less apoptosis cells 
(Figure 3). Therefore this indicates the pivotal role of p66Shc in diabetes-induced ROS 
production [58].  
The energy sensor---SIRT1 
SIRT1 belongs to histone deactylase class III (HDAC), which reverses protein acetylation and 
promotes DNA stability. SIRT1 also deacetylates a number of non-histone target protein, 
including tumor suppressor p53 protein [88, 89], members of the Forkhead transcription 
factor family (FoxO) [90-93], stress response protein ku70 and NF-κB [94, 95], and metabolic 
regulator PCG-1α [96]. Owing to a unique nicotinamide adenine dinucleotide (NAD+)-
dependent enzymatic activity, SIRT1 was recently considered as a promising therapeutic 
approach for aging and aging-associated cardiovascular diseases [97]. 
Starvation enhances the expression of SIRT1 protein in mouse liver and in human peripheral 
blood mononuclear cell, which returns to normal level upon feeding [90, 96]. The upregulated 
SIRT1 protein deacetylates PGC-1 α in a NAD+-dependent manner in both hepatic cells and 
mice livers, indicating a regulatory role of Sirt1 in the gluconeogenic/glycolytic pathway [96]. 
In a mouse model of chronic calorie restriction, which extends lifespan, the expression of 
SIRT1 protein is elevated in the calorie-restricted group [98]. Likewise, mice overexpressing 
SIRT1 share a similar phenotype to calorie-restricted mice, including lower body weight, 
lower cholesterol level, improved glucose homeostasis and increased metabolic rate [99]. 
Thus, SIRT1 is an important mediator of beneficial effects of calorie restriction, and is 
probably involved in lifespan control. 
The presence of SIRT1 protein was also observed in pancreatic β cell [100]. In cell culture 
experiments, inhibition of SIRT1 reduced the secretion of insulin, suggesting a possible target 
of SIRT1 for insulin secretion [100]. In Sirt1 knockout mice, insulin levels are reduced in 
both normoglycemic and glucose tolerance experiments. Consistently, in a type II diabetic 
mouse, genetic upregulation of SIRT1 [99, 101] or treated with resveratorl [102], a small 
molecule activator of SIRT1, enhances insulin secretion and thus improves glucose tolerance. 
These data underscore that the activator of SIRT1 is a potentially therapeutic principle for 
diabetes, especially for insulin-resistant type II diabetes.  
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SIRT1 also has beneficial effects on endothelial cells. In rat aorta, inhibition of SIRT1 ex vivo 
causes a blunted endothelium-dependent relaxation. Restoration of SIRT1 increases eNOS 
expression by deacetylation of eNOS on both lysine 496 and 506, indicating that SIRT1 
directly regulates eNOS [103]. In apoE knockout mice fed with high fat diet, the mouse 
overexpressing of endothelial cell-specific SIRT1 displayed a restored relaxation in the aorta 
accompanied by upregulated eNOS and a retarded atherogensis [104]. This result confirms a 
protective role of SIRT1 and eNOS for the development of atherosclerosis. Nevertheless, 
nitric oxide donor increases SIRT1 expression and delays cell senescence in human 
endothelial cells [105]. Calorie-restriction fails to enhance SIRT1 expression in eNOS 
knockout mice [98], suggesting that nitric oxide also modulates SIRT1 expression. Thus these 
data demonstrate a strong link between nitric oxide and SIRT1.  
Furthermore in the aorta of streptozotocin-induced diabetic mouse, the expression of SIRT1 
protein is reduced accompanied by higher levels of acetylated p53 and p21 expression [101]. 
resveratorl restores acetylated p53 and p21 in the aorta and thus improves endothelial 
dysfunction by down-regulating ICAM-1 expression and inhibiting leukocyte rolling [101], 
These data imply a protective role of SIRT1 in the pathogenesis of diabetic vascular 
dysfunction .  
In transgenic mice with heart-specific overexpression of SIRT1, beneficial effects are 
observed in mice with slightly or moderated upregulation of SIRT1 which is due to an 
increased catalase expression through FoxO-dependent signal pathway. Furthermore, the 
heart-specific overexpression of SIRT1 retards aging of the heart and further protects the heart 
from paraquat-induced oxidative stress [106].  
Clinic Perspective  
The proteins discussed in the present review represent different therapeutic targets for 
treatments of cardiovascular diseases, reducing cell damage or enhancing cell defenses.  
p66Shc protein is strongly linked to ROS production. The deletion of p66Shc prevents ROS-
mediated cell damage and therefore reduces cell apoptosis. Since the antioxidant treatments, 
proposed to decreases cardiovascular events, failed to reduce the risk of cardiovascular events 
in large, long-term clinical trials [107-109], the inhibition of p66Shc seems to be a more 
attractive therapeutic option to reduce oxidative stress in human.  
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SIRT1 exerts multiple protective effects. Physical training is reported to restore SIRT1 
protein in both heart and adipose tissue of aged mice [110], supporting the beneficial effect of 
exercise training [110-116]. Resveratrol, one of the polyphenolic compounds in grapes and 
wine, is reported as a small molecule activator of SIRT1 [117, 118]. Resveratrol increases 
insulin secretion in pancreatic β cell [102] and improves endothelial function in the aorta of 
diabetic mouse [101].  Besides, resveratrol reduces TNF-α-induced tissue factor expression 
through inactivating NF-κB mediate transcription [119] and thus prevents cells adhesiveness 
[120, 121]. In addition, resveratrol delays cell senescence via PI3K-Akt pathway in 
endothelial progenitor cells [122].  
Summary and conclusions 
p66Shc is a mitochondrial protein mediating oxidative stress. The inhibition of p66Shc 
reduces oxidative stress, suggesting that p66Shc is a promising target to reduced ROS 
mediated cardiovascular disease. SIRT1 is a protein sensitive to energy change in metabolism 
and improves cell survival and functions by deacetylating regulatory proteins. Upregulation of 
SIRT1 exhibits multiple beneficial effects on endothelial dysfunctions, especially in diabetes. 
It is optimistic to assume that either downregulating p66Shc, upregulating SIRT1, or 
combined both approaches could shift the imbalance towards normal level. These newly 
discovered target proteins offer insights to further understand underlying mechanisms of 
cardiovascular diseases (Figure 4).  
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Legends 
 
Figure 1. Schematic representation of the endothelium and some of its key derived vasoactive 
substances. The p66Shc is principally located in the mitochondria, where it contributes to the 
production of superoxide anion (O2-), radicals, which scavenge NO to form peroxynitrite 
(ONOO-). Different stress stimuli (e.g., glucose), increase in number and occurrence with age 
and enhance the production of O2-, thus exacerbating endothelial dysfunction. oxLDL, 
oxidized low-density lipoprotein; ET1, endothelin 1; NOS, NO synthase, ONOO, 
peroxynitrite; MCP-1, monocyte chemotactic protein-1; ICAM, intercellular adhesion 
molecule; VCAM, vascular cells adhesion molecule; NFkB, nuclear factor-kappa B; IkB, 
inhibitor to NFkB; NADPH, nicotinamide adenine dinucleotide phosphate-oxidase; PKC1, 
protein kinase C-1; GPx, glutathione peroxidase (39). 
 
 
Figure 2 a, Age-dependent changes in endothelium-dependent relaxation of WT and p66shc–
/– aortas. Line graphs show concentration–response curves to acetylcholine. Results are 
presented as mean±SEM; n=7 in each group. M/L indicates mol/L. *P<0.05 vs young WT. b, 
Bar graphs showing peak concentrations of NO in young (gray bars) and old (black bars) WT 
and p66shc–/– mice, respectively. Results are presented as mean±SEM; n=4 to 6 in each 
group. *P<0.05 vs young WT. (Francia et al., 2004). 
 
 
Figure 3 a)  Bar graphs show ONOO− levels determined by chemiluminescence. Results are 
presented as mean ± SEM; n = 6 in each group.  , P < 0.05 vs. control WT mice;   , P < 0.05 
vs. control WT mice. Immunostaining of nitrotyrosine residues in aortas from control and 
diabetic WT and p66Shc−/− mice is shown.  b ) TBARS levels. Bar graphs show TBARS 
levels in aortas from control and diabetic WT and p66Shc−/− mice. Results are presented as 
mean ± SEM; n = 4 in each group.  , P < 0.05 vs. control WT mice;   , P < 0.05 vs. control 
WT. (camici et al., 2007) 
 
 
Figure 4 Schematic representation of imbalance change between cell repair and cell damage 
under pathophysiological conditions and aging  . With aging,  the balance between noixous 
insults and cell protective systems lost in favor of the development of endothelial dysfunction 
and vascular diseases. The increased ROS production decreases anti-oxidant defense and 
reduces NO bioavailability. p66Shc and Sirt1, two newly discovered target protein offer 
insights to further understand underlying mechanisms of cardiovascular disease. ROS, 
reactive oxygen species; NO, nitric oxide.  
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